How to buy AbCellera Biologics stock (AbCellera Biologics)

AbCellera Biologics Inc. completed its initial public offering and its shares are now available on the Nasdaq under "ABCL." Vancouver-based AbCellera is an AI-powered drug discovery company working with Eli Lilly & Co. on a COVID-19 vaccine.

Our top picks for where to buy Abcellera Biologics Inc stock

Buy AbCellera Biologics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

AbCellera Biologics stock price (NASDAQ: ABCL)

Use our graph to track the performance of ABCL stocks over time.

AbCellera Biologics shares at a glance

• Key figures

Information last updated 2024-10-25.

Latest market close	$2.72
52-week range	$2.34 - $6.06
50-day moving average more info button	$2.60
200-day moving average more info button	$3.70
Wall St. target price	$15.43
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.53

Is it a good time to buy AbCellera Biologics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AbCellera Biologics price performance over time

Historical closes compared with the close of $2.72 from 2024-10-25

1 week (2024-10-17)	N/A
1 month (2024-09-27)	4.21%
3 months (2024-07-26)	-16.56%
6 months (2024-04-26)	-27.66%

1 year (2023-10-27)	-30.43%
2 years (2022-10-28)	-76.77%
3 years (2021-10-28)	15.92
5 years (2019-10-24)	N/A

AbCellera Biologics financials

Revenue TTM	$33.1 million
Gross profit TTM	$311.1 million
Return on assets TTM	-11.41%
Return on equity TTM	-13.3%
Profit margin	0%
Book value	$3.77
Market Capitalization more info button	$819.2 million

TTM: trailing 12 months

AbCellera Biologics share dividends

We're not expecting AbCellera Biologics to pay a dividend over the next 12 months.

You may also wish to consider:

AbCellera Biologics share price volatility

Over the last 12 months, AbCellera Biologics's shares have ranged in value from as little as $2.335 up to $6.055. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AbCellera Biologics's is 0.372. This would suggest that AbCellera Biologics's shares are less volatile than average (for this exchange).

To put AbCellera Biologics's beta into context you can compare it against those of similar companies.

• Genmab AS (GMAB.US): 0.86
• XBiotech (XBIT.US): 1.408
• Aridis Pharmaceuticals (ARDS.US): 1.099

AbCellera Biologics overview

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Frequently asked questions

null
What percentage of AbCellera Biologics is owned by insiders or institutions?
Currently 28.053% of AbCellera Biologics shares are held by insiders and 38.348% by institutions. How many people work for AbCellera Biologics?
Latest data suggests 586 work at AbCellera Biologics. When does the fiscal year end for AbCellera Biologics?
AbCellera Biologics's fiscal year ends in December. Where is AbCellera Biologics based?
AbCellera Biologics's address is: 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1 What is AbCellera Biologics's ISIN number?
AbCellera Biologics's international securities identification number is: CA00288U1066